Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Cobham break-up on target with warfare simulation sale - report

(Sharecast News) - US buyout firm Advent International is close to offloading a key division of Cobham, it was reported on Friday, as it continues to break up the defence giant. According to Sky News, Advent - which acquired the British business in 2019 for £4bn - is in "detailed negotiations" to sell Ultra Electronic Warfare Simulation Technology (EWST).

Cobham acquired EWST in 2021, when it bought London-listed Ultra Electronics in a £2.6bn deal.

Citing one unnamed potential bidder, Sky said EWST was unlikely to command a significant price.

But it will contribute to Advent's wholesale break-up of the once sprawling Cobham group. Assets already sold off include the Paris-based Cobham Aerospace Communications, which was snapped up by France's Thales in 2023 for £850m.

The decision to break up the business has been criticised by politicians, who are concerned it undermines the UK's defence industry during a period of heightened geopolitical unrest, and the founding Cobham family.

However, Advent has previously stated that Cobham was a large, disparate conglomerate and was struggling.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.